David Cragg - 01 Nov 2021 Form 4 Insider Report for CYTOKINETICS INC (CYTK)

Role
Chief HR & Admin Officer
Signature
By: Robert Wong For: David Cragg
Issuer symbol
CYTK
Transactions as of
01 Nov 2021
Transactions value $
-$722,240
Form type
4
Filing time
02 Nov 2021, 17:16:43 UTC
Previous filing
01 Oct 2021
Next filing
09 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYTK Common Stock Options Exercise $40.1K +6.68K +4.81% $6.00* 145K 01 Nov 2021 Direct F1, F2, F3
transaction CYTK Common Stock Sale -$233K -6.68K -4.59% $34.89 139K 01 Nov 2021 Direct F1, F2, F3
transaction CYTK Common Stock Options Exercise $110K +18.3K +13.21% $6.00* 157K 01 Nov 2021 Direct F1, F2, F3
transaction CYTK Common Stock Sale -$639K -18.3K -11.67% $34.89 139K 01 Nov 2021 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYTK Incentive Stock Option (right to buy) Options Exercise $0 -18.3K -100% $0.00* 0 01 Nov 2021 Common Stock 18.3K $6.00 Direct F2
transaction CYTK Non-Qualified Stock Option (right to buy) Options Exercise $0 -6.68K -100% $0.00* 0 01 Nov 2021 Common Stock 6.68K $6.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total.
F2 Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.
F3 Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.